Press release
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another study recently published in the
About this update from Lexicon Pharmaceuticals, Inc.
[{"type":"text","content":"New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another study recently published in the Journal of Comparative Effectiveness Research THE WOODLANDS, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the peer-reviewed Journal of the American College of Cardiology: Heart Failure has published a research paper concluding that INPEFA® (sotagliflozin) is cost-effective for people with diabetes and recent worsening heart failure using commonly accepted willingness-to-pay thresholds. “Our research team believes that this study is an important contribution to the economic evaluation of sotagliflozin, a novel SGLT inhibitor, from the perspective of the U.S. healthcare system. Our results demonstrated that in people with diabetes and recent worsening heart failure, sotagliflozin is cost-effective at commonly accepted willingness-to-pay thresholds,” said William S. Weintraub, MD, MACC, FAHA, FESC, director of Population Health Research at MedStar Health Research Institute, and the lead author of the research paper. The analysis was conducted from a U.S. healthcare sector perspective, in accordance with Consolidated Health Economic Evaluation Reporting Standards. Results from this study showed that lifetime quality-adjusted life-years (QALYs) were 4.43 and 4.04 in the INPEFA and placebo groups, respectively. In another study, “Cost-effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure,” recently published in the Journal of Comparative Effectiveness Research, the research team used published real-world data to derive baseline event frequencies and SOLOIST-WHF study data to estimate the efficacy of INPEFA. According to the research results, the use of INPEFA led to a net gain in QALYs of 0.425 for INPEFA versus standard of care. The investigators concluded that INPEFA is a cost-effective addition to standard of care for patients hospitalized with heart failure and comorbid diabetes. “The data published in these two peer-reviewed journals reinforce our position that in addition to providing meaningful clinical benefits to heart failure patients, INPEFA provides significant financial value for payors and the U.S. healthcare system,” said Craig Granowitz, M.D., Ph.D...